Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anthony V Moorman

Showing results (61-70 of 155) with videos related to

Pageof 16
Sort By:
Lancet (London, England)|December 7, 2010
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trialCatriona Parker, Rachel Waters, Carly Leighton, et al.
Blood|November 24, 2012
Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemiaToby Eyre, Claire J Schwab, Ross Kinstrie, et al.
British Journal of Haematology|October 30, 2009
Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993Bella Patel, Lena Rai, Georgina Buck, et al.
Blood|November 11, 2006
Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)Anthony V Moorman, Susan M Richards, Hazel M Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2017
Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic LeukemiaDavid O'Connor, Anthony V Moorman, Rachel Wade, et al.
Blood|November 26, 2010
Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trialHannah M Ensor, Claire Schwab, Lisa J Russell, et al.
Leukemia|April 10, 2024
Combination p53 activation and BCL-x<sub>L</sub>/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemiaHayden L Bell, Helen J Blair, Samantha J Jepson Gosling, et al.
British Journal of Haematology|October 22, 2021
Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe AmplificationClaire J Schwab, Daniel Murdy, Ellie Butler, et al.
Haematologica|March 10, 2018
Prognostic impact of the absence of biallelic deletion at the <i>TRG</i> locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trialNadine Farah, Amy A Kirkwood, Sunniyat Rahman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemiaAnthony V Moorman, Claire Schwab, Hannah M Ensor, et al.
Pageof 16

Showing results (61-70 of 155) with videos related to

Sort By:
Pageof 16
Lancet (London, England)|December 7, 2010
Effect of mitoxantrone on outcome of children with first relapse of acute lymphoblastic leukaemia (ALL R3): an open-label randomised trialCatriona Parker, Rachel Waters, Carly Leighton, et al.
Blood|November 24, 2012
Episomal amplification of NUP214-ABL1 fusion gene in B-cell acute lymphoblastic leukemiaToby Eyre, Claire J Schwab, Ross Kinstrie, et al.
British Journal of Haematology|October 30, 2009
Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993Bella Patel, Lena Rai, Georgina Buck, et al.
Blood|November 11, 2006
Prognosis of children with acute lymphoblastic leukemia (ALL) and intrachromosomal amplification of chromosome 21 (iAMP21)Anthony V Moorman, Susan M Richards, Hazel M Robinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2017
Use of Minimal Residual Disease Assessment to Redefine Induction Failure in Pediatric Acute Lymphoblastic LeukemiaDavid O'Connor, Anthony V Moorman, Rachel Wade, et al.
Blood|November 26, 2010
Demographic, clinical, and outcome features of children with acute lymphoblastic leukemia and CRLF2 deregulation: results from the MRC ALL97 clinical trialHannah M Ensor, Claire Schwab, Lisa J Russell, et al.
Leukemia|April 10, 2024
Combination p53 activation and BCL-x<sub>L</sub>/BCL-2 inhibition as a therapeutic strategy in high-risk and relapsed acute lymphoblastic leukemiaHayden L Bell, Helen J Blair, Samantha J Jepson Gosling, et al.
British Journal of Haematology|October 22, 2021
Genetic characterisation of childhood B-other-acute lymphoblastic leukaemia in UK patients by fluorescence in situ hybridisation and Multiplex Ligation-dependent Probe AmplificationClaire J Schwab, Daniel Murdy, Ellie Butler, et al.
Haematologica|March 10, 2018
Prognostic impact of the absence of biallelic deletion at the <i>TRG</i> locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trialNadine Farah, Amy A Kirkwood, Sunniyat Rahman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 2, 2012
IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemiaAnthony V Moorman, Claire Schwab, Hannah M Ensor, et al.
Pageof 16